Research Use Only - Not for human consumption. 18+ only.
Research CompoundMuscle Growth & PerformanceSubcutaneous

YK11

A myostatin inhibitor with SARM-like properties that promotes muscle growth by increasing follistatin levels. Uniquely acts as both a selective androgen receptor modulator and myostatin inhibitor.

Research Status

Research Compound

Early Research

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Increases muscle mass and strength
Enhances follistatin expression
Improves muscle protein synthesis
Supports lean body composition
May enhance athletic performance

Side Effects

Hepatotoxicity (liver stress)
UncommonModerate

YK11 is metabolized hepatically. Limited human data, but oral SARMs have shown liver enzyme elevation in some users. Monitor liver function tests (AST, ALT, bilirubin) if using. Discontinue if jaundice or severe abdominal pain develops.

Testosterone suppression
UncommonModerate

As an AR modulator, YK11 may suppress endogenous testosterone production through negative feedback. Post-cycle therapy (PCT) with SERMs may be considered after 8-12 week cycles, though evidence is limited.

Nausea or gastrointestinal upset
UncommonMild

May occur with oral administration, especially on an empty stomach. Take with food to minimize. Usually resolves within days of continued use.

Headache
RareMild

Reported anecdotally in some users. Typically mild and self-resolving. Ensure adequate hydration.

Acne or skin irritation
UncommonMild

Possible due to androgen receptor activation. Maintain good skin hygiene and consider dermatologist consultation if severe.

Hair loss (androgenic alopecia)
RareModerate

Possible in genetically predisposed individuals due to AR activation in hair follicles. Risk may be lower than traditional steroids but is not zero. Discontinue if significant hair loss occurs.

Mood changes or irritability
RareMild

Anecdotal reports of mood alterations. Monitor mental health and discontinue if significant mood disturbance occurs.

Unknown long-term effects
CommonSerious

YK11 has not been studied in humans. Long-term safety, efficacy, and potential organ toxicity are unknown. Use carries inherent research risk.

Dosing Reference

ParameterValue
Dose range5-10 mg
Frequency1x daily
TimingMorning, with food
RouteSubcutaneous

Oral administration. Research compound with limited human safety data. Often cycled 8-12 weeks with 4-week breaks. Not approved for human use.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

YK11 functions as a selective androgen receptor (AR) modulator with dual activity as a myostatin inhibitor. It promotes muscle growth by increasing follistatin expression, which suppresses myostatin — a negative regulator of muscle mass. Unlike traditional anabolic steroids, YK11 exhibits tissue-selective effects and may promote myogenic differentiation with reduced virilization potential, though human safety data remains limited.

Androgen Receptor Signaling

YK11 binds to and activates androgen receptors in muscle tissue, promoting anabolic gene expression and protein synthesis without full systemic androgenic effects

Myostatin Inhibition via Follistatin

YK11 increases follistatin production, which binds to and neutralizes myostatin, a negative regulator of muscle growth. This allows increased muscle protein synthesis and hypertrophy

Myogenic Differentiation

YK11 promotes the conversion of myoblasts into mature muscle fibers through enhanced differentiation pathways, contributing to increased muscle mass

  • YK11 is a non-steroidal selective androgen receptor modulator (SARM) with myostatin-inhibiting properties
  • Increases follistatin expression, which suppresses myostatin and promotes muscle growth
  • Promotes myogenic differentiation in cell culture without requiring classical androgen receptor-dependent virilization
  • Research is limited to in vitro and animal studies; human pharmacokinetics and long-term safety are not well-established
  • Not approved for human use by any regulatory agency

Track your YK11 research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. YK11 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.